COVID-19
Conditions
Keywords
SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus
Brief summary
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
Detailed description
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above. The participants were randomized into three groups of investigational vaccine 1, investigational vaccine 2 and placebo in a 1:1:1 ratio.2 doses of the investigational vaccine or placebo are inoculated into the deltoid muscle of the either arm according to the vaccination schedule of D0 & D21 (+7 days).According to the immune durability results in Phase I/II study, and cross-neutralization assay results, a third dose (booster dose) generates a better immune response and is estimated to offer better protection, therefore, a booster dose will be given after 3 months
Interventions
The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
BIOLOGICALPlacebo
The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Sponsors
G42 Healthcare company
Abu Dhabi Health Services Company
Wuhan Institute of Biological Products Co., Ltd
Beijing Institute of Biological Products Co Ltd.
China National Biotec Group Company Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects aged 18 years old and above. 2. By asking for medical history and physical examination, the investigator judged that the health condition is well. 3. Female subjects of childbearing age are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 3 months after enrolment. Effective contraceptive measures have been taken within 2 weeks before inclusion. 4. During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan. 5. With self-ability to understand the study procedures, the informed consent & voluntarily sign an informed consent form and be able to comply with the requirements of the clinical study protocol.
Exclusion criteria
1. Confirmed acute cases of SARS-CoV-2 Infection. 2. Have a history of SARS, MERS infection (self-report, on-site inquiry). 3. Positive urine pregnancy test result. 4. Fever (body temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination. 5. Axillary body temperature \> 37.0 ℃ before vaccination. 6. Previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated SARS-CoV-2 vaccine have occurred. 7. Has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. 8. With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. 9. With severe liver diseases, severe kidney diseases defined as eGFR less than 60, uncontrollable hypertension (systolic blood pressure \>150 mmHg, diastolic blood pressure \> 90 mmHg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. 10. Has been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases. 11. With known or suspected diseases include acute respiratory diseases (e.g. influenza like illness, acute cough, sore throat), severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. 12. Has a history of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation disease). 13. Receiving anti-TB therapy. 14. Patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). 15. Live attenuated vaccine is inoculated within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. 16. Received blood products within 3 months before this vaccination 17. Received other research drugs within 6 months before this vaccination. 18. Other circumstances judged by investigators that are not suitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of COVID-19 cases after two-doses of vaccination | From14 days after the second dose to 6 month after the second dose |
| The incidence of COVID-19 cases after the booster dose of immunization | From 14 days after the booster dose |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of any adverse reactions/events | 28 days after each immunization |
| The incidence of serious adverse events (SAE) | From the beginning of the first dose to 12 months after the second immunization |
| The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody | 14 days after full course of immunization |
| The Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody | 14 days after full course of immunization |
| The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody | 28 days, 3rd month, 6th month, 9th month, and 12th month after 2 doses of immunization |
| The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody | 14 days after full course of immunization |
| The incidence of severe cases of COVID-19 and deaths accompanied by COVID-19 after two-doses of vaccination | From 14 day after the second dose to 6 month after the second dose |
Other
| Measure | Time frame |
|---|---|
| the anti-SARS-CoV-2 neutralizing antibody protective level against COVID-19 | 14 days after 2 doses of vaccination |
| The occurrence of ADE | From the beginning of the first dose to 12 months after the second immunization |
Countries
Bahrain, Egypt, Jordan, United Arab Emirates
Outcome results
None listed